创新药ETF国泰（517110）涨超1.5%，创新药产业趋势不变

Group 1 - The core viewpoint is that the innovative pharmaceutical sector is experiencing sustainable growth due to the continuous implementation of BD, with a trend towards "innovation + internationalization" remaining unchanged [1] - After a short-term adjustment, the elasticity of the innovative pharmaceutical sector has further increased, indicating a positive outlook [1] - There is a noticeable improvement in the fundamentals of the innovative pharmaceutical industry chain, with positive trends observed in investment and financing data, orders, and performance [1] Group 2 - The Guotai Innovative Drug ETF (517110) tracks the SHS Innovative Drug Index (931409), which focuses on listed companies in the A-share and Hong Kong markets engaged in innovative drug research and biopharmaceuticals [1] - The index selects 50 high-growth and volatile constituent stocks, reflecting the overall performance of innovative pharmaceutical enterprises, with a growth-oriented style primarily allocated in the healthcare sector [1]